Arcus Biosciences, Inc. (RCUS) Earnings History
Annual and quarterly earnings data from 2016 to 2025
Loading earnings history...
RCUS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RCUS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 96.0% | -156.3% | -142.9% |
| 2024 | 100.0% | -127.9% | -109.7% |
| 2023 | 100.0% | -290.6% | -262.4% |
| 2022 | 100.0% | -250.0% | -238.4% |
| 2021 | 100.0% | 14.1% | 13.8% |
Download Data
Export RCUS earnings history in CSV or JSON format
Free sign-in required to download data
Arcus Biosciences, Inc. (RCUS) Earnings Overview
As of May 6, 2026, Arcus Biosciences, Inc. (RCUS) reported trailing twelve-month net income of -$369M, reflecting -4.8% year-over-year growth. The company earned $-2.94 per diluted share over the past four quarters, with a net profit margin of -142.9%.
Looking at the long-term picture, RCUS's historical earnings data spans multiple years. The company achieved its highest annual net income of $53M in fiscal 2021.
Arcus Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AGEN ($115,000 net income, 0.1% margin), EXEL ($833M net income, 33.7% margin), HALO ($317M net income, 22.7% margin), RCUS has room to improve margins relative to the peer group. Compare RCUS vs AGEN →
RCUS Earnings vs Peers
Earnings metrics vs comparable public companies
RCUS Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$353M | -24.7% | -$386M | $-3.29 | -142.9% | -156.3% |
| 2024 | -$283M | +7.8% | -$330M | $-3.14 | -109.7% | -127.9% |
| 2023 | -$307M | -15.0% | -$340M | $-4.15 | -262.4% | -290.6% |
| 2022 | -$267M | -603.8% | -$280M | $-3.71 | -238.4% | -250.0% |
| 2021 | $53M | +143.1% | $54M | $0.71 | 13.8% | 14.1% |
| 2020 | -$123M | -45.2% | -$124M | $-2.13 | -157.7% | -159.0% |
| 2019 | -$85M | -70.8% | -$89M | $-1.73 | -564.7% | -591.4% |
| 2018 | -$50M | +6.6% | -$55M | $-1.43 | -593.7% | -656.8% |
| 2017 | -$53M | -195.4% | -$53M | $-2.16 | -3756.7% | -3782.1% |
| 2016 | -$18M | - | -$18M | $-0.73 | - | - |
See RCUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RCUS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RCUS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRCUS — Frequently Asked Questions
Quick answers to the most common questions about buying RCUS stock.
Is RCUS growing earnings?
RCUS EPS of $-2.94 reflects slowing growth at -4.8%, below the 5-year CAGR of N/A. TTM net income is $-369M. Expansion rate has moderated.
What are RCUS's profit margins?
Arcus Biosciences, Inc. net margin is -142.9%, with operating margin at -156.3%. Below-average margins reflect competitive or cost pressures.
How consistent are RCUS's earnings?
RCUS earnings data spans 2016-2025. The current earnings trend is -4.8% YoY. Historical data enables comparison across business cycles.